IPS HEART has announced another important regulatory milestone after receiving FDA Rare Pediatric Disease Designation for ISX9-CPC, its investigational cardiac muscle therapy for Duchenne muscular dystrophy (DMD). Together with GIVI-MPCs, an experimental skeletal muscle therapy designed to generate new muscle and restore full-length dystrophin, the company is pursuing a regenerative approach that aims to address both cardiac and skeletal muscle damage.
Unlike many current treatment approaches that primarily focus on slowing disease progression, IPS HEART says its regenerative medicine platform is designed to create entirely new human muscle cells capable of producing full-length dystrophin.
A Different Strategy from Current DMD Therapies
Many currently available or experimental Duchenne treatments—including exon skipping therapies and micro-dystrophin gene therapies—help only specific groups of patients and generally do not restore the complete dystrophin protein.
In its press release, IPS HEART states that these approaches have clinical limitations and cannot restore full-length dystrophin, while its induced pluripotent stem cell (iPSC) platform is designed to generate new functional muscle cells expressing full-length dystrophin in preclinical studies.
The company is developing two separate regenerative therapies:
- ISX9-CPC for cardiac muscle
- GIVI-MPCs for skeletal muscle
Together, these therapies aim to regenerate damaged muscle rather than simply slow its deterioration.
ISX9-CPC: Regenerating Heart Muscle
Heart disease is one of the leading causes of death in Duchenne muscular dystrophy.
According to IPS HEART, ISX9-CPC is designed to replace fibrotic scar tissue in the heart with newly generated contractile cardiac muscle. Preclinical studies showed improved heart function and increased ejection fraction after treatment.
The company also highlights additional preclinical findings on its official website, stating:
“With ISX9-CPC, in an in vivo proof-of-concept peer reviewed study of a single treatment of our patented ISX9-CPC’s reduced dead scar tissue by 70% and restored heart function by over 60% EF improvement vs. control 90 days after heart attack.”
These findings relate to heart attack models rather than Duchenne patients, but IPS HEART presents them as evidence supporting the regenerative potential of its cardiac cell therapy.
GIVI-MPCs: Building New Skeletal Muscle with Full-Length Dystrophin
The company’s second program, GIVI-MPCs, focuses on regenerating skeletal muscle affected by Duchenne muscular dystrophy.
According to the press release, GIVI-MPCs is designed to generate new human skeletal muscle tissue while restoring full-length human dystrophin in multiple dystrophic animal models.
IPS HEART further expands on this claim on its official website, stating:
“With GIVI-MPC, we created significant new human skeletal muscle along with 100% full length human dystrophin in mdx mice and in dystrophic pigs.”
This is one of the strongest claims currently highlighted by the company because full-length dystrophin closely resembles the naturally occurring protein found in healthy muscle, unlike the shortened micro-dystrophin produced by current gene therapy approaches.
It is important to note, however, that these results are preclinical and have not yet been demonstrated in human clinical trials.
Human Clinical Trial Planned for 2027
IPS HEART says it plans to submit its Investigational New Drug (IND) application to the U.S. Food and Drug Administration and, pending regulatory clearance, begin its first-in-human clinical trial of GIVI-MPCs in 2027.
If approved to proceed, this would represent the first opportunity to evaluate whether the company’s regenerative strategy can safely restore skeletal muscle and full-length dystrophin in people living with Duchenne muscular dystrophy.
Why This Matters
One of the biggest scientific challenges in Duchenne research has been finding a way to replace lost muscle while restoring the complete dystrophin protein.
IPS HEART believes its regenerative cell therapy platform may eventually address both goals simultaneously:
- Regenerate damaged heart muscle
- Create new skeletal muscle
- Restore full-length dystrophin
- Potentially provide broader applicability than mutation-specific therapies
Whether these promising preclinical findings will translate into meaningful clinical benefits remains to be determined through carefully conducted human trials.
Explore Now: DMDWarrioR Clinical Trials Hub
